SRC and neoplasm: Since PD‐1, the receptor for PD‐L1, is one of the most potent suppressive molecules of T cells, inhibition of PD‐L1 expression by SRC‐1 deletion in CRC could activate T cells in TME to prevent tumor immune escape.